title: Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
abstract: Neuroendocrine tumors have a propensity to metastasize to the orbit, although the reason is unknown. A review of 251 neuroendocrine tumors treated with Lu-DOTATATE or I-MIBG at our institution since 2003 revealed 4 patients with orbital metastases (1.6%), 2 treated with Lu-DOTATATE and 2 with I-MIBG. Of these 4 patients, 1 patient was symptomatic with diplopia and eye pain, and 2 patients had physical signs of orbital involvement. The symptomatic orbital metastasis improved with Lu-DOTATATE therapy, and proptosis improved with I-MIBG therapy in 1 of 2 patients. We present the imaging findings of these 4 patients, as well as their management.
authors.affiliation: From the Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.
authors.forename: William
authors.initials: W
authors.lastname: Makis
authors.forename: Karey
authors.initials: K
authors.lastname: McCann
authors.forename: Alexander J B
authors.initials: AJ
authors.lastname: McEwan
mesh_terms: D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D006801:Humans; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009918:Orbital Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D009942:Organometallic Compounds / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; C447941:lutetium Lu 177 dotatate; D015282:Octreotide